Hongxingxianghe has completed nearly 100 million yuan in Pre-A round financing.

On September 17th, according to Arctic Aurora Venture Capital, recently, Hongxingxiang Life Sciences Co., Ltd. announced the completion of nearly 100 million RMB Pre-A round of financing. This round of financing was led by Arctic Aurora Venture Capital, with follow-up investments from Dongwei Fund, DCG Holdings, Dingfu Investment, Future Start-up Fund, and continuing participation from angel round shareholder Xingyaotaihao Fund. The funds from this round of financing will mainly be used to enrich and advance the pre-clinical and clinical POC research of the existing pipeline, while also comprehensively deploying AI platforms and biological organ platforms in the application of drug research and evaluation. The company will focus on building core capabilities in target and molecular drug evaluation, molecular and experimental design, and multi-dimensional outcome evaluation to effectively improve project proposal, decision-making efficiency, and R&D success rate.